SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-006412
Filing Date
2017-08-09
Accepted
2017-08-09 16:01:32
Documents
56
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q syrs-20170630x10q.htm 10-Q 1860338
2 EX-31.1 syrs-20170630ex311af6061.htm EX-31.1 10096
3 EX-31.2 syrs-20170630ex3122c9632.htm EX-31.2 10644
4 EX-32.1 syrs-20170630ex321ac0e6a.htm EX-32.1 7280
5 EX-32.2 syrs-20170630ex322c76815.htm EX-32.2 7295
  Complete submission text file 0001558370-17-006412.txt   5650709

Data Files

Seq Description Document Type Size
6 EX-101.INS syrs-20170630.xml EX-101.INS 1059784
7 EX-101.SCH syrs-20170630.xsd EX-101.SCH 33402
8 EX-101.CAL syrs-20170630_cal.xml EX-101.CAL 39184
9 EX-101.DEF syrs-20170630_def.xml EX-101.DEF 141191
10 EX-101.LAB syrs-20170630_lab.xml EX-101.LAB 371359
11 EX-101.PRE syrs-20170630_pre.xml EX-101.PRE 266438
Mailing Address 620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

IRS No.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37813 | Film No.: 171017790
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences